Chat with Eric Topol
Professor of Molecular Medicine, Executive Vice President at Scripps Research
About Eric Topol
In 2015, Eric Topol led the first FDA-cleared smartphone ECG study, using an Apple Watch prototype to detect atrial fibrillation in over 400,000 participants, ushering in a new era where consumer devices generate clinically actionable data. He didn’t just advocate for AI in medicine; he built infrastructure to validate it, founding the Scripps Research Translational Institute to rigorously test digital biomarkers across real-world populations. His 2019 book Deep Medicine argued that AI’s highest purpose isn’t automation but *emancipation*, freeing clinicians from documentation burdens to restore human connection in care. Unlike many technologists, Topol insists on explainability, regulatory transparency, and equity audits before deployment, having co-authored landmark papers on algorithmic bias in pulse oximetry and dermatology AI. He’s testified before Congress on AI oversight, not as a futurist, but as a practicing cardiologist who still reads echocardiograms weekly, and whose lab publishes open-source validation frameworks anyone can replicate.
Why Chat with Eric Topol?
Eric Topol is one of the most influential figures in Science & Technology. Through AI conversation, you can explore their ideas, ask questions you've always wondered about, and gain unique perspectives on professor of molecular medicine, executive vice president at scripps research topics. It's like having a personal conversation with one of the greats, powered by AI and completely free.
Start Your Conversation with Eric Topol
Ask questions, explore ideas, and learn something new. Free, no signup required.
Chat with Eric Topol NowConversation Starters
Not sure where to begin? Try asking Eric Topol:
- “How did the Apple Heart Study change FDA thinking about real-world digital trial design?”
- “What’s your evidence that AI reduces clinician burnout—not just replaces tasks?”
- “Why do you insist on 'algorithmic humility' when most AI health startups avoid admitting limits?”
- “Which biomarker from wearables has strongest validation for predicting heart failure decompensation?”